TMDX— AI Stock Forecast & Price Targets
Published 7/30/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TMDX price forecast →
TMDX's binary near-term thesis hinges on August 4 earnings confirming operational recovery from sequential margin compression and negative FCF. While elite underlying metrics (45% ROE, 59% GM) support long-term value, current price action shows range-bound behavior between $65-$75 with a technical breakout above $80 as the key trend-change signal.
Hold until August 4 earnings; price above $75 is bullish, below $65 invalidates the binary thesis. Avoid swing trades into earnings due to IV crush risk. Key levels: $80 breakout (bullish), $74.155 support (hold), $60.105 stop-loss (bearish).
If August 4 earnings confirm margin recovery and FCF sign-flip, target $82 as base with potential upside to $109. If not, reevaluate the thesis; current price action suggests accumulating buyers rather than sellers. Catalysts: Q3 revenue growth, European rollout progress.
TMDX's long-term value is anchored in its category-leading organ preservation franchise with elite unit economics (45% ROE, 59% GM). The kidney OCS launch into a $2.2B TAM and European expansion via PAD Aviation are key structural drivers. Biggest risk: failure to diversify revenue away from liver OCS concentration or regulatory setbacks.
Revenue growth remains robust (Q1 2026: $173.9M, +21% YoY) but sequential operating margin collapsed from 23.2% to 7.6% and FCF turned negative (-$12M), indicating operational challenges. Balance sheet strength is solid with a current ratio of 6.74 and cash reserves ($461.7M), though high debt ($863M) combined with negative FCF increases sensitivity to utilization stalls. Gross margins remain strong at 59%, but operating leverage realization is critical for margin recovery. Capital allocation appears focused on strategic growth (e.g., $400M convertible note issuance, PAD Aviation acquisition), yet the recent sequential margin collapse and negative FCF are concerning.
The chart shows a range-bound pattern between $65-$75 with no clear breakout above $80, aligning with prior analyst views. The Kronos AI forecast band (109.282-84.760) is significantly above current price ($78), indicating a potential upside but also highlighting the binary nature of the near-term thesis. Support levels are at $74.155 (actual) and $60.105 (52-week low), while resistance is at $82 (base target). The 24h drop of 4.93% suggests short-term volatility, but price action has been grinding higher into binary events rather than selling off.
Recent news highlights a mixed narrative: positive coverage from Motley Fool and ChartMill emphasizes TMDX's growth potential with strong earnings momentum, while Zacks' earnings preview for RXST (not directly related) adds noise. The key catalyst is the August 4 earnings report where management must reverse the sequential margin collapse and achieve FCF sign-flip to justify premium multiples. Analysts maintain a consensus target of $109-$129, but historical data shows bull targets rarely materialize—anchor near $82 as base.
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord